NCT06102408

Brief Summary

The first-line etiological workup is currently poorly codified, and some patients undergo sequential investigations. However, the reason which lead the clinician to perform subsequent exams, and the relevance of such exams, remain to be determined. The main objective of the study was to assess the relevance of a second-line workup of patients with uveitis.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
300

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2023

Shorter than P25 for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 22, 2023

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 26, 2023

Completed
20 days until next milestone

Study Start

First participant enrolled

November 15, 2023

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 15, 2023

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 25, 2023

Completed
Last Updated

October 27, 2023

Status Verified

October 1, 2023

Enrollment Period

1 month

First QC Date

October 22, 2023

Last Update Submit

October 25, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • patients undergoing a second line etiological workup

    percentage of patients undergoing a second line etiological workup

    through study completion, an average of 18 months

Study Arms (3)

Patients with only one etiological workup

patients who underwent only one set of exams for etiological investigations of uveitis

Other: second line investigations for uveitis etiological workup

Patients without diagnostic modification subsequently to the second etiological workup

Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was not modified by the second line investigations.

Other: second line investigations for uveitis etiological workup

Patients with diagnostic modification subsequently to the second etiological workup

Patients who underwent a second etiological workup, independently of the results of the fist line investigations, and whose diagnosis was modified by the second line investigations.

Other: second line investigations for uveitis etiological workup

Interventions

Biological, radiological or histological investigations performed after a first line etiological workup. Investigations conducted following abnormal resultats of first line exams were not considered as second line exams (e.g. : bronchoscopy performed after abrnomal CT scan).

Patients with diagnostic modification subsequently to the second etiological workupPatients with only one etiological workupPatients without diagnostic modification subsequently to the second etiological workup

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

adult pateints with uveitis requiring at least one etiological workup.

You may qualify if:

  • adult patient
  • at least one etiological workup in our center

You may not qualify if:

  • only episode of acute anterior uveitis quickly responding to topical treatments
  • diagnostic ophthalmologically obvious
  • opposition to collection of data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (6)

  • Hwang DK, Chou YJ, Pu CY, Chou P. Epidemiology of uveitis among the Chinese population in Taiwan: a population-based study. Ophthalmology. 2012 Nov;119(11):2371-6. doi: 10.1016/j.ophtha.2012.05.026. Epub 2012 Jul 17.

    PMID: 22809756BACKGROUND
  • Dandona L, Dandona R, John RK, McCarty CA, Rao GN. Population based assessment of uveitis in an urban population in southern India. Br J Ophthalmol. 2000 Jul;84(7):706-9. doi: 10.1136/bjo.84.7.706.

    PMID: 10873978BACKGROUND
  • Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005 Sep;140(3):509-16. doi: 10.1016/j.ajo.2005.03.057.

    PMID: 16196117BACKGROUND
  • Smith JR, Rosenbaum JT. Management of uveitis: a rheumatologic perspective. Arthritis Rheum. 2002 Feb;46(2):309-18. doi: 10.1002/art.503. No abstract available.

    PMID: 11840433BACKGROUND
  • Selmi C. Diagnosis and classification of autoimmune uveitis. Autoimmun Rev. 2014 Apr-May;13(4-5):591-4. doi: 10.1016/j.autrev.2014.01.006. Epub 2014 Jan 12.

    PMID: 24424168BACKGROUND
  • de Parisot A, Jamilloux Y, Kodjikian L, Errera MH, Sedira N, Heron E, Perard L, Cornut PL, Schneider C, Riviere S, Olle P, Pugnet G, Cathebras P, Manoli P, Bodaghi B, Saadoun D, Baillif S, Tieulie N, Andre M, Chiambaretta F, Bonin N, Bielefeld P, Bron A, Mouriaux F, Bienvenu B, Amamra N, Guerre P, Decullier E, Seve P; ULISSE group. Evaluating the cost-consequence of a standardized strategy for the etiological diagnosis of uveitis (ULISSE study). PLoS One. 2020 Feb 14;15(2):e0228918. doi: 10.1371/journal.pone.0228918. eCollection 2020.

    PMID: 32059021BACKGROUND

MeSH Terms

Conditions

Uveitis

Condition Hierarchy (Ancestors)

Uveal DiseasesEye Diseases

Central Study Contacts

Thomas Moulinet, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

October 22, 2023

First Posted

October 26, 2023

Study Start

November 15, 2023

Primary Completion

December 15, 2023

Study Completion

December 25, 2023

Last Updated

October 27, 2023

Record last verified: 2023-10